The Patient-Centered Outcomes Research Institute (PCORI) Board of Governors announced it will contribute $6.5 million to fund two studies that will examine the effectiveness of both newer and older anticoagulants for the prevention of blood clots.
Researchers from the University of California at San Francisco were awarded $3.5 million to review medical records of patients who took one of five anticoagulants (warfarin or a target-specific agents: apixaban, dabigatran, edoxaban, or rivaroxaban) for an extended period as a preventive measure or who stopped taking the drugs once their blood clots were resolved. The study also will compare the outcomes and risk-benefit ratios of each of the drugs in different patient populations, including older patients and those with impaired kidney function.
Researchers from Brigham and Women’s Hospital in Boston, Massachusetts, were awarded $2.9 million to compare the safety and effectiveness of each of the newer anticoagulants with each other, as well as with warfarin when used for an extended time. Researchers will also examine outcomes experienced for patients being treated for first-time clots.
“Blood clots in the veins and lungs can cause serious and sometimes deadly results such as organ damage, stroke, and heart attacks,” said PCORI Executive Director Joe Selby, MD, MPH. “The research we are supporting gives patients a vital role in finding the evidence on these newer medications that they, along with their providers, can use to make treatment decisions.”
Source: PCORI news release, July 19, 2016.